Key Growth Drivers Behind the Guidance Revision
The updated forecast is backed by several strategic operational developments. On the international level, Cupid has started its long-term contract with the Partnership for Supply Chain Management (PFSCM), Netherlands,a prominent international body coordinating global healthcare procurement. The company reports that this enhances its competitive edge in international healthcare supply chains as well as introduces a stable source of income.
Order visibility has also improved across private markets, institutional procurement, and international tenders spanning multiple geographies. The company highlighted growing demand from institutional buyers, private sector customers, and government procurement programmes as key contributors to the improved pipeline.
Business Verticals Performing Across the Board
In its product range, the business units dealing in Cupid’s Male Condom (MC) and Female Condom (FC) have been registering growth driven by better manufacturing capacity, customer acquisition, and market penetration in the past twelve months. The lubricant range is also making strides in institutional and retail markets.
The consumer business is being developed as a mainstream personal care and wellness brand, with the company expanding its presence across modern trade, organised retail, and pharmacy networks in India. In vitro diagnostics (IVD), equipment and tests used to analyse biological samples outside the body and menstrual cup tenders across multiple states represent another layer of activity, though management has kept its near-term growth projections for IVD deliberately conservative.
Palava Facility and Capacity Expansion
Cupid has also disclosed plans to operationalise its new manufacturing facility in Palava, Maharashtra, in the coming quarter. The company had acquired land at this location in March 2024 as part of a strategic capacity expansion. Once operational, the Palava unit is expected to augment annual production capacity by approximately 770 million male condoms and 75 million female condoms, representing roughly 1.5 times the existing output. This addition is intended to support sustained revenue growth while also improving operating efficiency.
Management Commentary of Cupid
Aditya Kumar Halwasiya, Chairman and Managing Director of Cupid Limited, said the strong start to FY27 shows the progress the company has made over the past few years in building a diversified business with multiple growth engines. He pointed to strong momentum in the international B2B business, expanding opportunities in private markets and government tenders, and the encouraging commencement of the PFSCM relationship as key factors. He also noted that profit margins are expected to remain strong, supported by favourable USD-INR realisations and an upward trend in pricing.
About Cupid Limited
Established in 1993, Cupid Limited is a manufacturer and brand owner of male and female condoms, water-based personal lubricants, IVD kits, deodorants, perfumes, almond hair oil, body oils, petroleum jelly, and other FMCG products. The company operates in more than 125 countries and holds WHO/UNFPA pre-qualification for both male and female condoms. It is the first company in the world to receive this dual pre-qualification. A substantial portion of its revenue is generated from international markets.
Conclusion
Cupid Limited's upward revision of its FY27 revenue guidance to ₹660 crore and above follows a Q1 FY27 performance that management describes as among the best in the company's history. The revision is supported by the commencement of the PFSCM supply agreement, improved order visibility across geographies, growth in condom and lubricant businesses, and the planned operationalisation of the Palava facility. The actual outcome for the full year will depend on the pace of order execution, regulatory approvals where applicable, and continued traction in both domestic consumer and international institutional markets.
